Multiple Myeloma Clinical Trials in Boston

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
G
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +17 more
2022-03-30
Mar 30, 2022
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +43 more
2022-03-28
Mar 28, 2022
K
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Recruiting
  • Multiple Myeloma
  • Gilbert, Arizona
  • +23 more
2022-04-04
Apr 4, 2022
T
A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)Therapy. A Phase 3, Randomized, Placebo-Controlled.
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Fountain Valley, California
  • +277 more
2022-03-23
Mar 23, 2022
G
A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Belantamab mafodotin frozen liquid
  • Belantamab mafodotin lyophilized powder
  • New Haven, Connecticut
  • +58 more
2022-03-21
Mar 21, 2022
P
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
Active, not recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +45 more
2022-03-29
Mar 29, 2022
J
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +35 more
2022-03-24
Mar 24, 2022
C
A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)
Active, not recruiting
  • Multiple Myeloma
  • bb2121 carfilzomib
  • +3 more
  • Scottsdale, Arizona
  • +18 more
2022-03-23
Mar 23, 2022
J
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +145 more
2022-03-24
Mar 24, 2022
J
A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Active, not recruiting
  • Multiple Myeloma
  • Whittier, California
  • +113 more
2022-03-24
Mar 24, 2022
J
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +152 more
2022-03-24
Mar 24, 2022
J
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +106 more
2022-03-24
Mar 24, 2022
J
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Daratumumab IV
  • +3 more
  • Birmingham, Alabama
  • +211 more
2022-03-24
Mar 24, 2022
J
A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +56 more
2022-03-24
Mar 24, 2022
J
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +158 more
2022-03-24
Mar 24, 2022
J
Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Part 1 (Dose Escalation): Daratumumab
  • +3 more
  • Boston, Massachusetts
  • +7 more
2022-03-24
Mar 24, 2022
J
A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +81 more
2022-03-24
Mar 24, 2022
J
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • Duarte, California
  • +21 more
2022-03-24
Mar 24, 2022
J
A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Little Rock, Arkansas
  • +145 more
2022-03-24
Mar 24, 2022
D
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Recruiting
  • Multiple Myeloma
  • Sample of Blood
  • Baltimore, Maryland
  • +2 more
2022-03-22
Mar 22, 2022
G
Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 5)
Recruiting
  • Multiple Myeloma
  • Belantamab mafodotin
  • +5 more
  • Atlanta, Georgia
  • +41 more
2022-03-23
Mar 23, 2022
A
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Recruiting
  • Refractory Multiple Myeloma
  • +2 more
  • Maywood, Illinois
  • +4 more
2022-03-19
Mar 19, 2022
B
Expanded Access Treatment Protocol CA204-143
No longer available
  • Multiple Myeloma
  • Elotuzumab in combination with Lenalidomide and Dexamethasone
  • Concord, California
  • +26 more
2022-03-17
Mar 17, 2022
D
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
Active, not recruiting
  • Multiple Myeloma
  • +3 more
    • Boston, Massachusetts
      Dana-Farber Cancer Institute
    2022-03-15
    Mar 15, 2022
    A
    A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Aurora, Colorado
    • +39 more
    2022-03-02
    Mar 2, 2022